Human PD-1/LAG-3 (Luc) Jurkat Reporter cell

• Genetically modified cell lines best reflect MOA (Mechanism of Action)
• Higher activity and larger assay window for robust and reproducible cell-based bioassay
• Comprehensive application data to support assay development and validation
• Full tracible record, stringent quality control and validated cell passage stability
• Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
• Global commercial license assistance whenever regulatory filing is required

The Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptors full length human PD-1 (Uniprot: Q15116) and LAG-3 (Uniprot: P18627-1), which can use to evaluate the synergistic effect of anti-human PD-1 and anti-human LAG-3 antibody. When co-cultured with target cells expressing human PD-L1 and MHCⅡ, the PD-1/PD-L1 and LAG-3/MHCⅡ interactions inhibit TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 and LAG-3/MHCⅡ interactions by the simultaneous addition of anti-PD-1 or anti-PD-L1 and anti-LAG-3 antibodies release the inhibitory signals and result in TCR activation and NFAT-mediated luminescence.

• Screen for anti-human PD-1 or/and anti-human LAG-3 antibody

Suspension

Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)

RPMI-1640 + 10% FBS

Serum-free cell cryopreservation medium

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

Frozen in liquid nitrogen.

Negative

Negative

See data sheet for detailed culturing and assay protocol.